STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #376 by analyst upside · 2026-06-27
NAGE
Niagen Bioscience, Inc.
Healthcare · Market Cap $272M · P/E 16.3x
ANALYST PRICE TARGET
+268.4%
implied upside to consensus target
Current Price $3.42
Consensus Target $12.6
Bull Target $18.0
Bear Target $10.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $3.29
52-Week High $14.69
YTD Return -45.3%
FUNDAMENTALS
Market Cap $272M
P/E Ratio (TTM) 16.3x
Forward P/E 10.7x
EPS (TTM) $0.21
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $130M
Profit Margin 14.3%
52-WEEK RANGE
52-Week Low $3.29
52-Week High $14.69
Current Price $3.42
Bear Target $10.0
Bull Target $18.0
● Now $3.42 ● Target $12.6
TRADING DATA
Avg Volume 823K
YTD Return -45.3%
Analyst Count 5
Consensus Buy
Upside to Target +268.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Niagen Bioscience, Inc. (NAGE) is currently trading at $3.42 with a Wall Street consensus price target of $12.6, implying potential upside of 268.4% over the next 12 months. 5 analysts currently cover NAGE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $10.0.

NAGE operates in the Healthcare sector with a market capitalisation of $272M. The stock is down 45.3% year-to-date and is currently trading near the lower end of its 52-week range of $3.29 – $14.69.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NAGE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-11 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-05 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-31 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-05 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-11-05 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-08-11 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-06-10 Building track record
Roth Capital — Reiterated
Buy → Buy 2025-06-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →